title: Phase II trial of temsirolimus in patients with metastatic breast cancer.
abstract: Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associated with estrogen receptor (ER) positivity. We therefore performed an open-label single arm phase II study of the rapamycin analog, temsirolimus, at a dose of 25 mg weekly, in women with pretreated breast cancers that were positive for ER, PR, or HER2. Archived formalin-fixed paraffin embedded tumor was collected for immunohistochemical evaluation of components of the PI3K/Akt/mTOR pathway and PIK3CA mutation analysis. Thirty-one patients were enrolled. There were no major objective responses; however, three patients had stable disease for over 24 weeks. Twenty-three tumor samples were available for mutational analysis. There were five tumors with PIK3CA mutations; no association was found between prolonged stable disease and PIK3CA mutation or any immunohistochemical marker. There was a trend toward improved progression free survival (PFS) for patients with positive nuclear staining for phospho-Akt308. One patient remains on study four and a half years after starting therapy; her tumor did not have a PIK3CA mutation. We conclude that single agent temsirolimus has minimal activity in a population of women with heavily pretreated breast cancer. We found no evidence that either absence of immunohistochemical staining for PTEN or mutations in the hotspot domains of PIK3CA in the primary tumor were associated with clinical benefit.
authors.affiliation: The University of Chicago Medical Center, 5841 South Maryland Ave., MC 2115, Chicago, IL 60637, USA. gfleming@medicine.bsd.uchicago.edu
authors.forename: Gini F
authors.initials: GF
authors.lastname: Fleming
authors.forename: Cynthia X
authors.initials: CX
authors.lastname: Ma
authors.forename: Dezheng
authors.initials: D
authors.lastname: Huo
authors.forename: Husain
authors.initials: H
authors.lastname: Sattar
authors.forename: Maria
authors.initials: M
authors.lastname: Tretiakova
authors.forename: L
authors.initials: L
authors.lastname: Lin
authors.forename: Olwen M
authors.initials: OM
authors.lastname: Hahn
authors.forename: F O
authors.initials: FO
authors.lastname: Olopade
authors.forename: R
authors.initials: R
authors.lastname: Nanda
authors.forename: Philip C
authors.initials: PC
authors.lastname: Hoffman
authors.forename: M J
authors.initials: MJ
authors.lastname: Naughton
authors.forename: Timothy
authors.initials: T
authors.lastname: Pluard
authors.forename: Suzanne D
authors.initials: SD
authors.lastname: Conzen
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Ellis
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D009154:Mutation; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; D020123:Sirolimus